Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
Patients with acute myeloid leukemia (AML) are at increased risk of thrombohemorrhagic complications. Overexpressed tissue factor (TF) on AML blasts contributes to systemic coagulation activation. We have recently shown that the heme enzyme myeloperoxidase (MPO) negatively regulates TF procoagulant activity (PCA) on myelomonocytic cells in vitro. We now aimed to further characterize the functional interaction of MPO and TF in AML in vivo. (Source: Thrombosis Research)
Source: Thrombosis Research - July 11, 2023 Category: Hematology Authors: Florian Langer, Hanna Quick, Antonia Beitzen-Heineke, Snjezana Janjetovic, Jonathan M äder, Carina Lehr, Carsten Bokemeyer, Piotr Kuta, Thomas Renné, Walter Fiedler, Lennart Beckmann, Felix Klingler, Christina C. Rolling Tags: Full Length Article Source Type: research
Estimation of the preanalytical activation of the contact system in coagulation tubes
Preanalytical problems may interfere with or affect the determination of certain biochemical quantities and should preferably be avoided. It is well-known that glass tubes may activate the contact system and initiate coagulation. Therefore, tubes used for coagulation assays are either plastic tubes or glass tubes coated with an inert material, e.g., silicone. But some coagulation assays such as the thrombin generation assay which is activated and initiated by tissue factor (TF), are particularly sensitive to contact activation, especially at low TF concentrations (1). (Source: Thrombosis Research)
Source: Thrombosis Research - July 11, 2023 Category: Hematology Authors: S øren Risom Kristensen, Jørgen Brodersen Gram, Jette Nybo, Johannes Jakobsen Sidelmann, Yaseelan Palarasah Tags: Letter to the Editors-in-Chief Source Type: research
DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network
Direct oral anticoagulants (DOACs), including apixaban, dabigatran, edoxaban, and rivaroxaban, are approved for the treatment and prevention of venous thromboembolism (VTE) and have become first-line agents for most patients. While dose adjustments are not recommended for the initial treatment of VTE by manufacturers of apixaban, dabigatran and rivaroxaban, limited evidence exists for the safety and efficacy of DOACs compared with warfarin in low weight patients. Phase III trials of DOACs in VTE included few underweight patients and did not include analyses of low weight categories [1 –3]. (Source: Thrombosis Research)
Source: Thrombosis Research - July 11, 2023 Category: Hematology Authors: Karlyn A. Martin, Nicola Lancki, Lisa Baumann Kreuziger, Celina Li, M. Elaine Eyster, Kristen Sanfilippo, Scott C. Woller, Rachel P. Rosovsky Tags: Letter to the Editors-in-Chief Source Type: research
Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D
Warfarin treatment quality is calculated as time in therapeutic range (TTR). TTR ≥ 70 % is considered reducing the risk of adverse events for patients with atrial fibrillation (AF). The association of TTR and adverse events in chronic kidney disease (CKD) is however poorly investigated. The aim is to explore this further. (Source: Thrombosis Research)
Source: Thrombosis Research - July 7, 2023 Category: Hematology Authors: Frida Welander, Henrik Renlund, Em öke Dimény, Henrik Holmberg, Anders Själander Tags: Full Length Article Source Type: research
Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL)
It is unclear whether hereditary hemorrhagic telangiectasia (HHT) patients can tolerate antithrombotic therapies (AT) including antiplatelet (AP) and/or anticoagulant (AC) agents. (Source: Thrombosis Research)
Source: Thrombosis Research - July 6, 2023 Category: Hematology Authors: Vincent Grobost, Sami Hammi, Bruno Pereira, Alexandre Guilhem, Pierre Duffau, Julie Seguier, Antoine Parrot, Giovanni Gautier, Laurent Alric, Mallorie Kerjouan, Xavier Le Guillou, Delphine Simon, Laurent Chaussavoine, Murielle Rondeau-Lutz, Vanessa Leguy- Tags: Full Length Article Source Type: research
Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension
The objective of this study was to determine if DOAC is an effective and safe alternative to VKA in CTEPH patients. (Source: Thrombosis Research)
Source: Thrombosis Research - July 6, 2023 Category: Hematology Authors: Ilham Benzidia, Chantal Robitaille, Ali Abualsaud, Laura McDonald, Lyda Lesenko, Jean-Fran çois Morin, David Langleben, Susan R. Kahn, Andrew Hirsch Source Type: research
Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis
Chronic kidney disease is an independent risk factor for venous thromboembolism (VTE). Traditionally, Low Molecular Weight Heparin (LMWH) followed by warfarin has been the conventional therapy for VTE treatment. Direct oral anticoagulants (DOACs), including apixaban, have shown several advantages over the traditional therapy in individuals with normal kidney function. This meta-analysis aims to review the safety and efficacy of apixaban compared to warfarin or LMWH for the treatment of VTE in severe renal failure. (Source: Thrombosis Research)
Source: Thrombosis Research - July 3, 2023 Category: Hematology Authors: Anwar Almajdi, Sara Almuteiri, Maha Alharbi Tags: Full Length Article Source Type: research
Venous and arterial thromboembolism after colorectal cancer in the Netherlands: Incidence, predictors, and prognosis
Colorectal cancer (CRC) is the third most prevalent cancer type. CRC-patients are at increased risk of venous and arterial thromboembolism (TE), but the magnitude of the risks, their predictors and consequences are not exactly known. (Source: Thrombosis Research)
Source: Thrombosis Research - July 3, 2023 Category: Hematology Authors: R.J.S. Anijs, Q. Chen, T. van der Hulle, H.H. Versteeg, F.A. Klok, W.M. Lijfering, S.C. Cannegieter Tags: Full Length Article Source Type: research
Rare-variant collapsing analyses reveal novel risk genes for arterial and venous cardiovascular diseases in the UK biobank
Cardiovascular diseases (CVDs) are a major cause of mortality [1,2]. Genome wide association studies (GWAS) have identified CVD linked variants but there is still missing heritability for common CVDs [2,3]. Whole exome sequencing (WES) studies may reveal the contribution of rare variants to common diseases [2,3]. However, few large-scale WES studies have been published until Wang et al. reported the relationships between rare protein-coding variants and 17,361 binary phenotypes using WES data from 269,171 UK Biobank participants (https://azphewas.com/) [4]. (Source: Thrombosis Research)
Source: Thrombosis Research - July 3, 2023 Category: Hematology Authors: Bengt Z öller, Eric Manderstedt, Christina Lind-Halldén, Christer Halldén Tags: Letter to the Editors-in-Chief Source Type: research
Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation
HIV-infected individuals are known to be at higher risk for thrombotic cardiovascular disease (CVD), which may also be differentially affected by components of anti-HIV drugs. To identify the effects of a series of FDA-approved anti-HIV drugs on platelet aggregation in humans, focusing on the novel pharmacological effects of rilpivirine (RPV), a reverse transcriptase inhibitor, on platelet function both in vitro and in vivo and the mechanisms involved. (Source: Thrombosis Research)
Source: Thrombosis Research - July 1, 2023 Category: Hematology Authors: Kui Liu, Zhen Hao, Hao Zheng, Haojie Wang, Luying Zhang, Minghui Yan, Reyisha Tuerhong, Yuling Zhou, Yan Wang, Tao Pang, Lei Shi Tags: Full Length Article Source Type: research
Force-induced biphasic regulation of VWF cleavage by ADAMTS13
It is crucial for hemostasis that platelets are rapidly recruited to the site of vascular injury by the adhesive ligand von Willebrand factor (VWF) multimers. The metalloproteinase ADAMTS13 regulates this hemostatic activity by proteolytically reducing the size of VWF and its proteolytic kinetics has been investigated by biochemical and single-molecule biophysical methods. However, how ADAMTS13 cleaves VWF in flowing blood remains poorly defined. To investigate the force-induced VWF cleavage, VWF A1A2A3 tridomains were immobilized and subjected to hydrodynamic forces in the presence of ADAMTS13. (Source: Thrombosis Research)
Source: Thrombosis Research - June 30, 2023 Category: Hematology Authors: Jiangguo Lin, Xiaoru Ding, Pu Yang, Silu Liu, Quhuan Li, Miguel A. Cruz, Jing-fei Dong, Ying Fang, Jianhua Wu Tags: Full Length Article Source Type: research
Argininemia and vitamin K-dependent coagulation factors deficiency: A case report and a brief review of the literature
Arginase deficiency (AD) is caused by an autosomal recessive mutation in the gene coding for arginase 1 (ARG1). The estimated prevalence of AD is 1 per 950,000 births, which corresponds to around 3 % of all urea cycle disorders (UCDs) (1). After birth, UCDs result in the accumulation of ammonia; this causes neurologic impairments, liver disorders, gastrointestinal tract problems, and psychiatric disorders (1–3). Relative to other UCDs, the signs of AD are milder and start to appear later (1–3). Low blood levels of vitamin K-dependent coagulation factors (VKCFD) like FVII, FIX, FX and protein C have been reported, an...
Source: Thrombosis Research - June 29, 2023 Category: Hematology Authors: Tasnim Bel Hadj, Val érie Li Thiao Te, Maïlys Le Guyader, Annelise Voyer, Charlotte Durand-Maugard, Antoine Galmiche, Loïc Garçon, Julien Demagny Tags: Letter to the Editors-in-Chief Source Type: research
What do we know about platelets in myocardial ischemia-reperfusion injury and why is it important?
Myocardial ischemia-reperfusion injury (MIRI), the joint result of ischemic injury and reperfusion injury, is associated with poor outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Accumulating evidence demonstrates that activated platelets directly contribute to the pathogenesis of MIRI through participating in the formation of microthrombi, interaction with leukocytes, secretion of active substances, constriction of microvasculature, and activation of spinal afferent nerves. (Source: Thrombosis Research)
Source: Thrombosis Research - June 29, 2023 Category: Hematology Authors: Lun Wang, Yifan Liu, Ran Tian, Wei Zuo, Hao Qian, Liang Wang, Xinglin Yang, Zhenyu Liu, Shuyang Zhang Tags: Review Article Source Type: research
Editorial Board
(Source: Thrombosis Research)
Source: Thrombosis Research - June 28, 2023 Category: Hematology Source Type: research
Plasma levels of coagulation factors VIII and IX and risk of venous thromboembolism: Systematic review and meta-analysis
The associations of plasma factor VIII (FVIII) and factor IX (FIX) levels with risk of venous thromboembolism (VTE) are not well defined. We performed a systematic review and meta-analysis of these associations. (Source: Thrombosis Research)
Source: Thrombosis Research - June 27, 2023 Category: Hematology Authors: Gordon Lowe, Olivia Wu, Astrid van Hylckama Vlieg, Aaron Folsom, Frits Rosendaal, Mark Woodward Tags: Full Length Article Source Type: research
